Grabar Law Investigates SLNO: Don’t Miss This Opportunity!

Introduction

Soleno Therapeutics (NASDAQ: SLNO) is a biotechnology company thrust into the spotlight after its lead product launch was followed by controversy and legal scrutiny. The company’s share price skyrocketed in early 2025 on news of its first FDA-approved drug, but later plummeted amid safety concerns and a high-profile short-seller report (www.marketscreener.com). In the wake of these events, multiple shareholder rights law firms – including Grabar Law Office – began investigating potential misconduct. For instance, Bragar Eagel & Squire, P.C. announced in August 2025 that it was examining whether Soleno’s management misled investors (www.bespc.com), and by November 2025 Robbins Geller Rudman & Dowd LLP had launched a federal securities investigation involving Soleno (www.placera.se). Most recently, a class-action lawsuit was filed alleging that Soleno downplayed critical safety risks in its clinical trial data (www.globenewswire.com). This report will delve into Soleno’s fundamentals – from its dividend policy and financial leverage to valuation metrics and red flags – to help investors weigh the opportunity and risks surrounding SLNO in light of these developments.

Company Overview: Rare Disease Focus and Breakthrough Drug

Soleno Therapeutics is a biopharma company focused on rare diseases, best known for developing VYKAT™ XR (diazoxide choline extended-release). Approved by the FDA in March 2025, VYKAT XR is the first-ever therapy to address hyperphagia (insatiable hunger) in patients with Prader-Willi syndrome (PWS) (investors.soleno.life). PWS is a rare genetic disorder with no previous treatment for its most debilitating symptom, and Soleno’s drug now fills a critical unmet need. In the CEO’s words, the approval was a “significant milestone” for the PWS community, which had “no options to treat the most disruptive aspect of this disease” until now (investors.soleno.life). Early feedback suggested high pent-up demand – within weeks of approval, Soleno reported a “high level of interest” in VYKAT XR reflected by numerous patient enrollment forms and new prescribing physicians (soleno.gcs-web.com). Management asserted that, “with a strong balance sheet and a world-class team,” Soleno was well positioned to sustain its momentum delivering VYKAT XR to patients while creating long-term value (soleno.gcs-web.com).

However, this optimistic narrative has since been challenged by adverse developments. In August 2025, Scorpion Capital, a noted short-seller, published a damning 415-page report alleging serious problems with VYKAT XR’s safety and Soleno’s trial integrity (aijourn.com) (aijourn.com). According to the report, there was a “rapid pile-up” of pediatric patients hospitalized for potential heart failure shortly after starting VYKAT XR, raising fears that the drug might be withdrawn from the market (aijourn.com). Scorpion also claimed Soleno used “hocus-pocus” launch metrics to obscure an overreliance on a controversial physician known for questionable PWS therapies (aijourn.com). The short report even alleged Soleno’s Phase 3 trials were essentially a “sham”, citing suspect data and whistleblower comments from former employees (aijourn.com). Then, on September 10, 2025, Soleno disclosed that a patient on VYKAT XR had died – an event recorded in the FDA’s adverse event database – which sent the stock down over 12% in a single day (www.marketscreener.com). Together, these safety concerns and allegations have cast a shadow over Soleno’s breakthrough, prompting legal probes that continue to unfold.

Dividend Policy and Shareholder Yield

Soleno Therapeutics has never paid a dividend, and it does not expect to initiate any dividends in the foreseeable future (www.sec.gov). This is typical for a development-stage biotech: the company has accumulated a large deficit through years of R&D and only just reached its first quarter of profitability in late 2025. Both management’s stated policy and its financing agreements reinforce the no-dividend stance. In fact, Soleno’s credit facility covenants explicitly prohibit dividend payments or other capital distributions (www.sec.gov) (www.sec.gov) – a common requirement designed to ensure cash is reinvested in the business or reserved for debt service. Instead of dividends, Soleno has focused on funding its drug development and now the commercial launch of VYKAT XR. Shareholders’ returns, therefore, depend entirely on stock price appreciation (or depreciation), which in Soleno’s case has been volatile. After a reverse stock split and subsequent FDA approval, SLNO shares surged from the low single-digits to as high as the mid-$80s in 2025 (edgar.secdatabase.com), but later fell back into the $40–$50 range following the safety scare and broader market pullback (finance.yahoo.com).

Notably, Soleno did capitalize on its high share price by raising equity capital – effectively returning value by fortifying the balance sheet. In July 2025, the company issued ~2.7 million new shares at $85.00 each, garnering approximately $230 million in gross proceeds (edgar.secdatabase.com). This timely financing, done near the stock’s peak, benefited existing shareholders indirectly by reducing the need for additional debt or dilutive financings at lower prices. Still, with no dividend income and a high-risk profile, Soleno is not an investment for income-oriented investors. Any yield for shareholders will come via future stock gains, which are contingent on the company’s execution and risk mitigation rather than any steady cash payout (www.sec.gov).

(AFFO/FFO Note:) Metrics like Funds From Operations (FFO) or Adjusted FFO are not applicable to Soleno. Those metrics are used for REITs and other cash-flowing asset companies; Soleno, by contrast, only recently started generating revenue from product sales and has significant ongoing R&D and commercial expenses. Given its history of net losses (and negative operating cash flow until this year), there are no meaningful “funds from operations” to adjust – essentially all cash has been reinvested or consumed by operations. Investors evaluating Soleno must instead focus on its future earnings potential and cash burn/runway rather than FFO or dividend yield.

Financial Leverage and Debt Maturities

Soleno’s balance sheet has been significantly strengthened in 2025, leaving it with ample liquidity and moderate debt. As of September 30, 2025, the company held $246.7 million in cash plus $309.4 million in marketable securities, for a total of roughly $556 million in liquid assets (edgar.secdatabase.com). This liquidity was bolstered by the mid-2025 equity offering and initial VYKAT XR sales. On the debt side, Soleno has a loan facility with Oxford Finance LLC that provides up to $200 million in term loans (edgar.secdatabase.com). By Q3 2025, only $50 million of this facility had been drawn (the initial tranche), and no additional debt had been taken despite another $50 million tranche becoming available post-FDA approval (edgar.secdatabase.com). The outstanding $50 million term loan is interest-only for 48 months, with principal repayment scheduled to begin in 2029 and final maturity by late 2029 or 2030 (subject to milestone-based extensions) (edgar.secdatabase.com) (edgar.secdatabase.com). In other words, Soleno faces no significant debt principal payments until at least 2029, a favorable structure that defers repayment until VYKAT XR has had time to hopefully generate substantial cash flow.

Interest expense on the Oxford loan is manageable: the debt carries a floating rate of 1-month SOFR + 5.5% (edgar.secdatabase.com), which equated to roughly a 10–11% annual rate in 2025. On $50 million, this implies about $5 million of annual interest cost. In fact, Soleno’s interest cost for the first nine months of 2025 was about $4.1 million (edgar.secdatabase.com). Thanks to the large cash cushion, the company actually earned more in interest income from its investments (over $11.8 million in the same nine-month period) than it paid out in interest expense (edgar.secdatabase.com) (edgar.secdatabase.com). This means Soleno currently enjoys net interest income, which effectively subsidizes its debt cost. Even without that, the interest coverage ratio has turned positive alongside Soleno’s recent profitability – for the third quarter of 2025, Soleno reported operating profits well in excess of its ~$1.4 million quarterly interest expense (edgar.secdatabase.com). All told, Soleno’s leverage appears conservative: with net cash of roughly $500 million (cash and investments minus debt) and a debt-to-capital ratio under 10%, the company is financially flexible. It has the option (but not the need) to draw further debt ($75 million remained available in future tranches as of Q3) (edgar.secdatabase.com), and covenants require maintaining certain cash and revenue minimums by 2026 but impose no immediate strains (edgar.secdatabase.com) (edgar.secdatabase.com). One important covenant is that Soleno cannot pay dividends or make large acquisitions without lender consent (www.sec.gov) (www.sec.gov) – reinforcing that cash will stay dedicated to growth initiatives and debt service.

In summary, Soleno’s leverage profile is strong for a company at this stage. Its long-term debt is relatively small and low-cost given current cash flows, and near-term solvency is buttressed by the substantial cash reserves raised at a favorable equity price. Investors should monitor that debt doesn’t increase significantly unless matched by earnings, but at present Soleno’s balance sheet risk is low compared to many biotech peers. The key financial challenge lies not in debt, but in successfully turning its cash into a profitable return via VYKAT XR’s commercialization and possibly pipeline expansion.

Valuation and Performance Metrics

Valuing Soleno Therapeutics requires a forward-looking approach, as traditional trailing metrics are skewed by the company’s transition from R&D to commercial stage. For example, Soleno’s trailing twelve-month earnings per share are still negative (≈–$1.81 EPS) due to heavy losses in early 2025, so its P/E ratio is not meaningful (finance.yahoo.com). Likewise, backward-looking cash flow metrics are of limited use since Soleno only began generating revenue in Q2 2025 and turned its first quarterly profit in Q3 2025 (edgar.secdatabase.com). Instead, investors are valuing SLNO based on anticipated growth and ultimate profitability of VYKAT XR in the PWS market (and potential future markets).

As of late 2025, Soleno’s market capitalization hovered around $2.5–$2.7 billion (finance.yahoo.com) (with roughly 53.7 million shares outstanding post-offering). To put this in context, the stock traded near $50/share in December 2025, which is about 10.0 times the annualized Q3 2025 revenue run-rate. In Q3, Soleno recorded $66 million in net product revenue (edgar.secdatabase.com), which if sustained would equate to ≈$264 million yearly. Given that Q3 was only the second quarter of sales – and showed strong sequential growth from ~$32.7 million in Q2 to $66.0 million in Q3 (net) (edgar.secdatabase.com) – investors expect significant further revenue growth as more PWS patients begin treatment. If one were to project, say, $300–$400 million in sales for 2026, the current valuation equates to roughly 6–9× forward sales. Such a multiple is not unusual for a recently launched orphan drug with an open field (VYKAT XR is first-to-market) and potentially high pricing power. Moreover, Soleno’s Q3 2025 net profit margin was on the order of 40% (net income $26 million on $66 million revenue) (edgar.secdatabase.com), suggesting the drug – if its safety profile holds up – could be extremely lucrative once initial launch investments are absorbed. A high margin, high growth orphan drug can justify premium valuation multiples.

That said, the validity of Soleno’s valuation hinges on the assumption that VYKAT XR’s launch trajectory remains on track. Before the safety scare, at least five Wall Street analysts were covering Soleno, and consensus price targets reportedly averaged around $100+ per share, implying a bullish view on long-term prospects. The company’s management also sounds confident: they highlighted that the rapid uptake of VYKAT XR (number of patient start forms and unique prescribers) reflects “significant unmet need” in PWS and bodes well for continued growth (soleno.gcs-web.com). However, since the negative news emerged, Soleno’s stock has underperformed and its beta has been highly negative (–3.15 5Y beta) (finance.yahoo.com), indicating the stock has been moving opposite the market – likely driven by company-specific events rather than broader sector trends. The current market cap also factors in Soleno’s half-billion in cash (which alone accounts for nearly 20% of the market cap), meaning enterprise value is somewhat lower. In summary, by P/E or P/FFO, SLNO looks expensive (since earnings are just starting), but by EV/Sales or considering orphan biotech comparables, the valuation reflects optimism tempered by recent risk. Investors are effectively paying for a potentially transformative rare-disease franchise and a cash-rich balance sheet, while assigning a discount for the uncertainties discussed below.

Risks and Red Flags

While Soleno’s fundamental story is compelling, the risks are substantial, and recent events have illuminated several red flags:

– Drug Safety Concerns: The foremost risk is the safety profile of VYKAT XR. Prader-Willi patients desperately need treatment for hyperphagia, but not at the cost of life-threatening side effects. The short-seller report by Scorpion Capital alleged that VYKAT XR had caused multiple cases of cardiac failure in children shortly after starting the drug (aijourn.com). It even suggested the drug might be pulled from the market due to these issues (www.marketscreener.com). These claims gained some credibility when Soleno confirmed a patient death in September 2025 potentially linked to VYKAT XR (the case was reported in the FDA’s FAERS database) (www.marketscreener.com). Although FAERS reports alone do not prove causation (and Soleno has noted that such adverse events can result from underlying PWS complications and lack crucial context (edgar.secdatabase.com) (edgar.secdatabase.com)), the news understandably rattled investors and physicians. If additional severe adverse events emerge, the FDA could impose new warnings or even suspend the drug’s use pending investigation. Soleno has a Risk Evaluation and Mitigation Strategy (REMS) in place for VYKAT XR (common for potent orphan drugs), but it’s unclear if current measures are sufficient. This is an existential risk: since VYKAT XR is Soleno’s sole commercial product, any serious safety setback would crater the company’s prospects.

– Allegations of Misconduct and Data Integrity: Beyond the safety outcomes themselves, Scorpion’s report raised red flags about Soleno’s transparency and trial rigor. It claimed Soleno “systematically…concealed significant evidence of safety concerns” during its Phase 3 DCCR trials (www.globenewswire.com). The short report also described Soleno’s pivotal withdrawal study as having “red flags for suspect data/results,” implying that the efficacy and safety data might not be as strong as presented (aijourn.com). These are serious accusations – essentially questioning whether Soleno misled regulators and investors about VYKAT XR’s true risk-benefit profile. Soleno’s management has denied wrongdoing, but the issue is now in legal forums. Shareholder lawsuits (class actions) have been filed, such as one by Bragar Eagel & Squire in March 2026, alleging that Soleno’s officers made false or misleading statements regarding the trial data and drug safety (www.globenewswire.com). Robbins Geller and Rosen Law have similarly publicized investigations into whether Soleno failed to disclose material adverse information (www.placera.se). Even Grabar Law Office, as noted in the title of this report, is seeking long-term shareholders who believe Soleno’s board breached its fiduciary duties – for example, by not properly disclosing risks or by failing to fulfill oversight responsibilities (a pattern Grabar has pursued at other companies) (www.globenewswire.com). While the merits of these claims are yet to be adjudicated, the sheer number of law firms circling suggests that something was amiss or at least not well-handled by Soleno’s leadership. At minimum, the company faces distraction, legal expenses, and reputational damage. At worst, if evidence shows intentional misrepresentation, consequences could include leadership changes or penalties. Investors should monitor updates from these legal cases, as they could unearth internal documents or testimony shedding light on what Soleno’s executives knew about VYKAT XR’s risks and when they knew it.

– Single Product Dependency: Even aside from the current controversy, Soleno is a classic “one-product biotech.” Virtually all its eggs are in the VYKAT XR basket. The company’s pipeline beyond PWS is scant – VYKAT XR (formerly DCCR) was originally acquired from Essentialis in 2017, and any additional indications or follow-on compounds are in very early stages or theoretical. Management hasn’t announced any new clinical programs of note, and a planned study of DCCR in a related condition has not been prominently detailed. This lack of diversification means that any obstacle for VYKAT XR (clinical, regulatory, commercial, or competitive) directly threatens the entire company. By contrast, larger biopharma companies can fall back on multiple revenue streams if one asset stumbles. For Soleno, commercial execution risk is also heightened: it must build out marketing, physician education, reimbursement support, and distribution essentially from scratch for one drug. Notably, Soleno relies on one specialty pharmacy distributor to deliver VYKAT XR to patients (edgar.secdatabase.com). While this focused approach can efficiently reach the rare disease community, it also concentrates risk – any disruption with that partner or supply chain issues at the single 3PL (third-party logistics provider) could halt product availability. Moreover, the pricing of VYKAT XR (reportedly high, given orphan drug norms) must be justified to insurers. There is a risk that payers could impose strict prior authorizations or step therapy (though there is no alternative therapy, they might still require demonstration of diet interventions first, etc.). If insurance hurdles make access difficult, uptake could slow despite patient need.

– Uncertain Market Size and Trajectory: Prader-Willi syndrome is ultra-rare, which makes forecasting Soleno’s revenue challenging and prone to error. PWS is estimated to occur in ~1 in 15,000 births (investors.soleno.life), translating to perhaps 20,000–30,000 cases in the U.S. (and similar in Europe). Not all of those will be eligible or seek out VYKAT XR (due to age limits, disease severity, or other factors). Soleno’s projections for patient uptake could prove optimistic, especially if safety concerns cause some physicians or families to take a “wait and see” approach. Early sales might include bolus demand from the most severe cases, but sustaining growth will require penetrating a larger portion of the PWS population and possibly treating younger patients over many years. There is also the question of global expansion: Soleno indicated plans to make VYKAT XR available in the EU by mid-2025 on a named-patient basis (soleno.gcs-web.com), but formal European Medicines Agency approval has not been announced yet. Launching in Europe (or other regions) would likely require significant investment or a partnership with a larger pharma, and success is not guaranteed given varying healthcare systems and pricing controls abroad. Any delays or setbacks in geographic expansion would cap the drug’s ultimate sales. Finally, competition could emerge: while no other PWS hyperphagia drug is approved, academic centers are exploring treatments (e.g. oxytocin analogs, cannabinoid-based drugs, etc.), and big pharma’s interest in rare disease appetite pathways (such as GLP-1 agonists for obesity) could eventually encroach on PWS treatment if repurposed or studied in this population. Soleno will need to innovate and maintain goodwill with the patient community to fend off any future competitors – a task made harder if its reputation is tarnished by safety problems or lawsuits.

– Management and Governance Questions: The unfolding legal drama raises questions about Soleno’s management credibility and internal controls. The company’s CEO and team successfully navigated FDA approval, which is commendable, but did they adequately prepare for and respond to the post-approval responsibilities? For instance, critics might ask if Soleno was slow to disclose the patient death – the fatal case was publicly reported on Sept. 10, but did it occur earlier? The timing of disclosures can be contentious in securities litigation. Also, the heavy use of stock-based compensation (over $34 million in non-cash comp expense in the first nine months of 2025) (edgar.secdatabase.com) means management and directors have significant equity incentives; while this aligns them with shareholders in success, it could also encourage overly optimistic messaging. The board’s oversight will likely come under the microscope (by Grabar Law and others) to assess if they exercised sufficient diligence in risk management. Any findings of weak governance or internal dissent (e.g., if whistleblowers from inside the company corroborate the short-seller’s claims) would be a red flag for investors. On the other hand, if Soleno’s leadership navigates through this storm by being transparent and proactive – for example, conducting additional studies to confirm safety or engaging an external advisory board to monitor adverse events – it could rebuild confidence. At the moment, however, uncertainty over management’s handling of the situation is itself a risk factor.

In sum, Soleno faces a convergence of high-impact risks right now. The company’s fortunes hinge on VYKAT XR’s safety and acceptance. Investors should carefully monitor FDA communications (e.g. any signal of a label update or investigation into the drug), physician sentiment (are prescriptions still rising quarter-to-quarter or stalling?), and the progression of investor lawsuits. These will be key indicators of whether the current issues are transient or a sign of deeper problems.

Open Questions and Future Outlook

Given the rapidly evolving situation with Soleno Therapeutics, several open questions remain unanswered:

– Will VYKAT XR remain on the market without additional restrictions? Both investors and patients need clarity on whether the reported adverse events are isolated incidents or part of a pattern. An FDA safety review is likely underway. Can Soleno demonstrate that VYKAT XR’s benefits outweigh its risks, and might the FDA impose a black-box warning or other mitigations? The outcome will greatly influence Soleno’s prospects.

– How strong is the ongoing demand and uptake trend? Early sales were encouraging, but it’s unclear if the momentum will continue or if the safety controversy has dampened new prescriptions. Will physicians keep prescribing VYKAT XR at the prior pace? The next few quarterly reports should reveal if revenues are growing as expected or plateauing. Any guidance from management on patient counts or refill rates will be telling.

– What will be the resolution of the legal investigations? As multiple law firms pursue Soleno, a key question is whether any evidence of wrongdoing emerges. Will the class action lawsuit uncover internal documents that validate the short-seller’s assertions of data concealment? Or will Soleno successfully defend its conduct? A settlement could be costly (though likely covered by insurance), whereas a protracted fight could distract management for years. The commitment of firms like Robbins Geller and Grabar Law signals that shareholders are pushing for accountability – possibly even changes in corporate governance or executive roles if trust is broken.

– How will Soleno deploy its substantial cash reserves? With over half a billion dollars in cash and equivalents (edgar.secdatabase.com), Soleno has the rare luxury (for a small biotech) of a war chest. This raises strategic questions: Will the company double down on VYKAT XR – for instance, funding expanded access programs, global launches, or post-marketing studies to strengthen the drug’s profile? Or will Soleno seek to diversify its pipeline through acquisitions or in-licensing another rare disease asset? Investors will be watching for any indications of M&A or new pipeline candidates. Using the cash wisely to generate future growth (beyond PWS) could unlock additional value, whereas idle cash or ill-advised deals could frustrate shareholders.

– Can Soleno restore confidence among stakeholders? Beyond the numbers, a broader question is whether Soleno’s management can repair its reputation with investors, physicians, and the PWS community. Trust is crucial for a company selling a therapy for a vulnerable population. Open communication about safety monitoring, publishing comprehensive data, and engaging with patient advocacy groups will be part of this effort. The company’s ability to navigate public relations and stakeholder outreach in the coming months may determine if SLNO is seen as a turnaround story or a cautionary tale.

In conclusion, Soleno Therapeutics stands at a crossroads. The company reached an impressive milestone by bringing VYKAT XR to market and even achieved profitability on an operating basis (edgar.secdatabase.com) – a rare feat for a small biotech launching its first product. However, serious clouds have gathered in the form of safety questions and legal challenges. The phrase “Don’t Miss This Opportunity!” could be read two ways: as a rallying cry for those who believe the stock is undervalued if these issues resolve, or as an ironic warning that opportunistic law firms are circling a wounded company. A prudent analysis suggests that potential investors in SLNO should be prepared for volatility. Diligence is required on upcoming clinical data releases, legal filings, and management’s actions. There is significant upside if Soleno can dispel the red flags – PWS is a real market need, and VYKAT XR could be a long-term cash cow with no competition. But at the same time, the downside risk is profound if events take a further negative turn. In the end, whether this situation becomes a rewarding opportunity or a value trap will depend on how effectively Soleno navigates the risks and executes in the coming quarters. As always in biotech, the motto is: “hope for the best, but prepare for the worst.”

Sources: (investors.soleno.life) (investors.soleno.life) (www.marketscreener.com) (www.placera.se) (www.bespc.com) (www.globenewswire.com) (aijourn.com) (aijourn.com) (soleno.gcs-web.com) (www.sec.gov) (www.sec.gov) (edgar.secdatabase.com) (finance.yahoo.com) (edgar.secdatabase.com) (edgar.secdatabase.com) (edgar.secdatabase.com) (edgar.secdatabase.com) (edgar.secdatabase.com) (edgar.secdatabase.com) (www.marketscreener.com) (edgar.secdatabase.com)

For informational purposes only; not investment advice.